We profiled AquaLiv, Inc. (AQLV) on September 18th, 2011. Since then AQLV shares gradually gaining a market value. We expect AquaLiv’s news concerning their NatuRx(TM) HIV/AIDS treatment in Kenya to be on market wires at any week now:
[…] AquaLiv CEO, Craig Hoffman, stated:
“Unlike traditional drugs, all NatuRx(TM) treatments are information-based and do not rely on chemical interaction with active molecules to function. The Kenyan authorities recognized that our unique treatment has a negligible toxicity and cannot be misused. It is impossible to overdose. In our first regulatory organization experience with NatuRx(TM), the treatment was acknowledged and understood far easier than we anticipated.”
Mr. Hoffman continued,
“Even more exciting than this warm welcome is the outcome of an approved registration as an alternative medicine. If approved, we will be able to market and sell NatuRx(TM) HIV/AIDS without further clinical trials. And, approval could be granted in the next 30-60 days. The biggest hurdle in biotech is regulatory approval for sale and ongoing costs of continued clinical trials. This will be a big a win for AquaLiv.”
AquaLiv Technologies Inc.
4550 NW Newberry Hill Road Suite 202
Silverdale, WA 98383
AquaLiv, Inc. is a life sciences research and development company. Recent advancements in AquaLiv’s technology uncovered a new field of biological information science. With direct applications in the industries of water purification, environmental science, agriculture, animal husbandry, personal use products, and medicine, AquaLiv is ready to expand its innovative product offering.